Health and wellness firms dominate list of the fastest-growing in Britain
Health and fitness brands are among Britain's fastest-growing companies as entrepreneurs across the country tap into blossoming lifestyle trends, new rankings show.
Research for the annual Sunday Times 100 found that Glasgow-based activewear brand DFYNE took the top spot this year.
The business, which sells gym attire for men and women, enjoyed a more than 500% increase in sales on average over the past three years.
It made nearly £67 million in sales in the year to May.
In the number two spot is Healf, a London-based retailer selling health products from vitamins and minerals to fitness watches and sleep masks.
The company's sales increased more than fivefold on average over the past three years, with it making £40 million in the latest year, the research found.
Other firms included in the top 20 that have tapped into the burgeoning demand for wellness include Ancient + Brave, a brand selling collagen and dietary supplements, and Rheal, a Sunderland-based superfoods retailer.
Sportswear brand Montirex and health-focused meal delivery firm Simmer Eats also clinched a spot in the annual list.
The Sunday Times 100, a network of reporters from across the Times newspapers, compiled the fourth annual list by examining sales growth figures across private companies – excluding those selling their own technology, which feature in a separate table.
Elsewhere, Nala's Baby, which sells skincare and haircare products for children and babies, was number 10 in the rankings having enjoyed sales growth of 175% over the past three years.
The brand was founded by Casyo Johnson – otherwise known as Krept, one half of UK rap duo Krept & Konan – with co-parent Sasha Ellese in 2022.
The research also found that, of the 100 companies featured in the rankings, more than a third (36) are based in London, with the rest spread throughout the country.
There were 28 businesses included this year that have female founders or co-founders, including fashion brand Odd Muse, in fourth place, and jewellery business D.Louise, in ninth.
About half of the companies on the list trade internationally, according to the research.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
19 minutes ago
- The Sun
New Ozempic alternative only needs to be taken once a month and leads to ‘substantial weight loss'
A NEW weight loss jab that only needs to be taken once monthly leads to "substantial weight loss", according to early trials. Drugs like Wegovy and Mounjaro - or diabetes jab Ozempic - need to be injected once weekly to see results. 1 But a new drug currently being trialled by pharmaceutical company Amgen can be given once a month and saw users shed up to 16 per cent of their body weight over the course of a year. This is bellow the 20 per cent weight loss than can be achieved through Mounjaro - dubbed the 'King Kong' of weight loss jabs - over 18 months. But scientists behind the new trial said the less frequent dose schedule could encourage people to stick to the treatment. The drug is called maridebart cafraglutide, or MariTide for short. Like Wegoy, Mounjaro and Ozempic, it's a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it targets the GLP-1 receptors in the brain and pancreas to reduce appetite and control blood sugar. But it also targets glucose-dependent insulinotropic polypeptide (GIP) receptors, which are also involved in managing insulin release, fat storage, metabolism, and appetite. This is part of the reason the drug needs to be administered less often. "In this phase two trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes," they wrote in The New England Journal of Medicine. "Once-monthly therapeutics for obesity may offer sustainable treatment for persons with this highly prevalent, chronic disease. "Medication at less frequent intervals may improve adherence and reduce barriers, potentially facilitating improvements in long-term health outcomes." There were 592 people aged 18 or older enrolled in the study - 465 of them were obese, defined as having a BMI of 30 or more, or a BMI of 27 with one obesity-related complication. The remaining participants had obesity as well as type 2 diabetes. They were randomly given monthly maridebart cafraglutide injections or a placebo for a year, at dose of 140, 280, or 420 mg. Some participants remained on a stable dose throughout, while others gradually worked up to a higher one. Participants were asked to report any side effects they experienced from the drug, such as nausea, vomiting, retching, headaches, diarrhoea and constipation Those with obesity lost 12.3 to 16.2 per cent of their body weight while taking maridebart cafraglutide over 52 weeks, compared to people taking a placebo who only lost 2.5 per cent of their weight. As for people with diabetes and obesity, they lost 8.4 to 12.3 per cent of their body weight on the drug, compared to 1.7 per cent weight loss for placebo-takers. Almost all participants taking maridebart cafraglutide experienced at least one side-effect from the drug - mild to moderate nausea, vomiting and retching were the most frequently reported side-effects. These effects were less severe when participants gradually built up to a full dose of maridebart cafraglutide, which may be the best way to get people started on it in the future. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Two deaths were reported in participants who received maridebart cafraglutide, but both were investigated and deemed unrelated to the drug. A handful of people taking the drug reported gallbladder issues, which can also be an issue with other weight loss jabs. Some also experienced depression and suicidal thoughts while participating in the trial. One person taking maridebart cafraglutide and one person on the placebo drug withdrew as a result. This was a phase two clinical trial, meaning it still needs to be tested on a bigger group of participants over a longer time period. Amgen deemed the results promising enough to progress to a phase three trial. "This phase two dose-ranging trial investigating the efficacy and safety of maridebart cafraglutide, a long-acting GLP-1 receptor agonist and GIP receptor antagonist administered once monthly or less frequently, showed substantial weight reduction and no new or unexpected safety signals, supporting advancement to phase three," researchers wrote. They estimated MariTide could lead to even more weight loss, beyond a year of use. they noted.
The Sun
19 minutes ago
- The Sun
Are the Universal Credit and PIP cuts going ahead? We explain how changes could affect you
LATE-NIGHT concessions were granted to Labour rebels on the flagship welfare reforms - giving relief to some benefits claimants. Ministers announced a slew of welfare reforms back in March aimed at getting more people off sickness benefits and into work. 1 Changes outlined included curbing access to the main disability benefit known as Pip - personal independence payment - and sickness-related universal credit. But hopes of Chancellor Rachel Reeves saving around £5 billion by the end of the decade have been dashed by 126-strong army of Labour MPs voicing their opposition. What are the Pip changes? Welfare Secretary Liz Kendall says ANYONE currently receiving Pip will keep their benefits. Only new claims kicking in from November NEXT year will fall under the new criteria under beefed-up eligibility requirements. The new measures would have seen 800,000 people lose out with an average loss of £4,500 every year. The changes would have seen a staggering 370,000 people totally lose the Pip pay-outs. What isn't changing to Pip? Welfare Secretary Liz Kendall says ANYONE currently receiving Pip will keep their benefits. The Institute for Fiscal Studies (IFS) said the change will also indirectly boost around 50,000 carers who look after someone on Pip, ensuring they keep their carer's allowance of around £4,340 per year. What are the Universal Credit changes? More than 2 million people will see themselves protected from a loss of between £250 and £500 a year. Increases to UC will see a boost of £7 a week to £106 per week for new and existing claims from April 2026. What isn't changing to Universal Credit? The Cabinet Minister vowed that all those currently receiving the UC health element - and new claimants meeting the severe conditions criteria will see their incomes 'fully protected in real terms'. But Mikey Erhardt, from Disability Rights UK, accused the Government of 'playing politics with our lives', saying the vote next Tuesday must still be pulled. He said the changes will mean 'a benefits system where future generations of disabled people receive less support than disabled people today'. He added that the original decision 'prioritised balancing its books over improving the lives of disabled citizens'. Mr Erhardt added: 'Despite seemingly rowing back on some of the worst aspects of its plans, the Government is still attempting to slash billions of pounds from a system that doesn't provide enough support as it stands.' The MS Society said Ministers were simply 'kicking the can down the road and delaying an inevitable disaster'. They urged MPs 'not to be swayed by these last-ditch attempts to force through a harmful Bill with supposed concessions'. Food bank network Trussell welcomed the 'significant' concessions. But they said the proposals 'still present a bleak future for future claimants and still risk placing the Government's commitments to end the need for emergency food and tackle poverty in serious jeopardy'.
Daily Mail
19 minutes ago
- Daily Mail
SMALL CAP MOVERS: Spring could be here after a three-year deep freeze
After more than three years of deep freeze, liquidity dried up, valuations languished, and investor apathy reigned, there are signs of a tentative spring. Cavendish, the boutique investment bank with a front-row seat to the UK's small and mid-cap market, has just signalled a change in the weather. According to commentary alongside its full-year results this week, there are three drivers: a weakening US dollar, rising political risk stateside, and a growing sense among global investors that being overexposed to America may be more of a bug than a feature. As portfolios rebalance, undervalued UK equities, particularly smaller ones, are starting to get a second look. Cavendish's optimism isn't just PR gloss. It's grounded in a strong pipeline of private equity dealmaking and a rising tide of founder exits. Interesting, then, that against this backdrop Cavendish, born from the merger of small-cap brokers finnCap and Cenkos, has landed in the middle of bid speculation. An approach from private equity-backed accountancy firm Smith & Williamson to acquire Cavendish's M&A arm sent shares up 25 per cent to 13.76p. The enquiry was promptly rebuffed. Now, onto the wider market. Underlining Cavendish's point, the AIM All Share rose 1.1 per cent to 768.20, its highest level since last August. The FTSE 100 was flat. Top of the leader board was Autins, the automotive insulation firm, which surged 64 per cent after announcing it was on track to make its first net profit since 2017. Ariana Resources also impressed, unveiling a major uplift in the economics of its Dokwe gold project in Zimbabwe. Proactive flagged it earlier as one to watch after it missed the sector's rerating. Dokwe, conservatively valued at around £250 million, appears to have lit the blue touch-paper, with shares up 38 per cent. Turning to the debit column, the week's biggest faller was Dekel Agri-Vision, the West Africa-focused farming group, which dropped 38 per cent following a deeply discounted £2 million fundraising and debt conversion. Arkle Resource, the gold and zinc explorer chaired by veteran Irish entrepreneur John Teeling, sank 39 per cent after prelims showed the firm is running on fumes. It ended last year with £23,000 in the bank, then raised £270,000. Investors were told more capital can be raised 'as required' - the market is braced for a dilutive, discounted cash call. Mosman Oil & Gas also had a rocky week, falling 30 per cent after a failed helium drill in Colorado. While the crew moves on to the next well, it was the end of the road for CEO Andy Carroll. Next 15 endured a turbulent 24 hours. The PR and marketing group behind City spin shop MHP issued a doozy of a profit warning on Thursday, prompting the CEO's departure and a boardroom reshuffle, plus a sharp drop in the share price. No sooner had the rollercoaster hit bottom than bid interest emerged, with an unnamed buyer circling the group's 'legacy' advertising and PR business. Shares bounced 8 per cent on Friday but still ended the week down 25 per cent, and 42 per cent lower year to date. Finally, a breakthrough for Zanaga Iron Ore. The company has made a metallurgical leap that could transform the economics of its flagship Republic of Congo project. Test work confirms Zanaga can now produce direct reduction iron (DRI) grade pellet feed—essential for the fast-growing electric arc furnace (EAF) steel sector. DRI-grade feedstock must meet tight specs. According to Panmure Liberum, Zanaga's samples exceeded them, with iron content over 68.5 per cent and low impurities. Crucially, the upgrade appears cost-neutral. As Panmure put it: 'There should be no expectation of any significant change to capital and operating costs as a result.' The shares ended Friday up 8 per cent at 8.34p.
